Sait Selcuk Atici

Sait Selcuk Atici

Auto-generated profile, based on publicly available information

Sait Selcuk Atici

Department of Anesthesiology, Selcuk University, Medical Faculty, Konya, Turkey

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2017 in Pain Research and Management
Verified
Journal Article
Open access
PDF file
FCFaruk Cicekci
Faruk Cicekci
CSCigdem Sizer
Cigdem Sizer
SASait Selcuk Atici
Sait Selcuk Atici
ŞAŞule ARICAN
Şule ARICAN
AKAdnan Karaibrahimoglu
Adnan Karaibrahimoglu
IKInci Kara
Inci Kara
Objectives.We aimed to assess the effects of levobupivacaine and of levobupivacaine + adrenaline administered during pediatric tonsillectomy on the postoperative period.Methods.A total of 90 patients between the ages of five and twelve were divided randomly into two groups before tonsillectomy: levobupivacaine only (0.5%) 0.4 mg·kg−1or levobupivacaine (0.5%) 0.4 mg·kg−1+ adrenaline (1 : 200.000) administered by means of peritonsillar infiltration. Primary outcomes were postoperative pain scores recorded at various intervals until 24 hours postoperatively. Secondary outcomes included postoperative nausea and vomiting (PONV), time to first oral intake, time to the first administration of analgesics and total consumption of analgesics, and the amount of bleeding for all children.Results.In both groups, patients had the same postoperative pain scores and PONV rates, and equal amounts of analgesics were consumed up to 24 hours postoperatively. The two groups also had the same time until first oral intake, recovery time and time to the first analgesic request, and amount of bleeding.Conclusions.Perioperative levobupivacaine infiltration on its own is a valid alternative to the combination of levobupivacaine + adrenaline for perioperative and postoperative effectiveness in pediatric tonsillectomy. This trial is registered with Australian New Zealand Clinical Trial Registry ACTRN:ACTRN12617001167358.